drugset / Trial / NCT03752138
TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia
Non-randomizedSequentialOpen-labelTreatment
Summary
This phase I trial studies the side effects and best dose of TK216 and decitabine when given together in treating patients with acute myeloid leukemia that has come back or does not respond to treatment. Drugs used in chemotherapy, such as TK216 and decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Timeline
- Start
- 2019-03-31
- Primary completion
- 2020-12-31
- Completion
- 2020-12-31
Outcome
Outcome not reported
Stopped: “The supporting pharamceutical company elected not to pursue this study at this time.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Decitabine | Small molecule | 10 mg/m2 | Intravenous |
| Subject | Decitabine | Small molecule | 20 mg/m2 | Intravenous |
| Subject | TK216 | Unknown | 144 mg/m2 | Intravenous |
| Subject | TK216 | Unknown | 288 mg/m2 | Intravenous |